GlobeNewswire EN Nachrichten

 

CALGARY, Alberta, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Canacol Energy Ltd. (TSX: CNE) (OTCID: CNNEQ) (BVC: CNEC) (“Canacol” or the “Company”) announces that it has entered into an agreement with an ad hoc group of holders of the Company's 5.75% senior unsecured notes due 2028 (the “DIP Credit Agreement”) for debtor-in-possession financing (the “DIP Financing”), comprised of a U.S.$45 million delayed-draw new-money term loan (the “Term Loan Tranche”) with capacity to obtain additional commitments to issue up to U.S.$22 million in letters of credit to renew and/or replace certain existing letters of credit (the “LC Tranche”). The DIP Financing will bear customary DIP interest and fees, will mature on June 30, 2026 (with a three-month extension option subject to conditions), and, subject to court approval, will be secured by a court-ordered super-priority charge over all of the Company's and its operating subsidiaries' assets, subject only to a court-ordered super priority administr...

FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of its upsized underwritten public offering of 16,250,000 shares of its common stock at a public offering price of $40.00 per share, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are expected to be $650 million, excluding any exercise of the underwriters' option to purchase additional shares. Terns has granted the underwriters a 30-day option to purchase up to an additional 2,437,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on December 11, 2025, subject to customary closing conditions. All of the securities are being offered by Terns....

WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $602.0 million of shares of its common stock. Kymera is selling 7,000,000 shares of common stock in the offering, which are being sold at a public offering price of $86.00 per share. In addition, Kymera has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The gross proceeds to Kymera from the offering are expected to be approximately $602.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Kymera, assuming no exercise of the underwriters' option to purchase additional shares. All of the securities being sold in ...

SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the pricing of its upsized underwritten public offering of 8,461,538 American depositary shares (ADSs), each representing three ordinary shares, at a price to the public of $65.00 per ADS and pre-funded warrants to purchase 1,538,462 ADSs at a price to the public of $64.9999 per pre-funded warrant. All of the securities in the offering are being sold by Structure Therapeutics....

LOS ANGELES, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global shared intelligent electric mobility ecosystem company, today announced that it has launched the start of assembly production of the FX Super One MPV pre-production vehicles at the Company's Hanford, CA factory in anticipation of the first pre-production vehicle off the line ceremony planned for December 21. This milestone also marks the near completion of the Bridge Closure for the Company's Bridge strategy, covering a closed loop of supply chain, testing, logistics, customs clearance and production. This further validates the feasibility and strategic value of the Bridge model, across tariff adaptation, ICTS compliance, cost management, and operational efficiency....

CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), announced today the pricing of its previously announced underwritten public offering of 15,789,475 of its ordinary shares at a price to the public of $19.00 per ordinary share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 2,631,578 ordinary shares at an offering price of $18.9999 per pre-funded warrant, which represents the per share offering price for the ordinary shares less the $0.0001 per share exercise price for each pre-funded warrant....

WALTHAM, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an upsized underwritten public offering of 18,980,478 shares of its common stock at a public offering price of $18.44 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $350.0 million. All shares in the offering are being sold by Dyne. The offering is expected to close on or about December 11, 2025, subject to customary closing conditions. In addition, Dyne has granted the underwriters a 30-day option to purchase up to an additional 2,847,071 shares of its common stock at the public offering price, less the underwriting discounts and commissions....

SUMMIT, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Leapfrog Acquisition Corporation (the "Company") announced today the closing of its initial public offering of 14,375,000 units, which includes the exercise in full by the underwriters of their overallotment option to purchase 1,875,000 units. The offering was priced at $10.00 per unit, generating total gross proceeds of $143,750,000. The units commenced trading on December 5, 2025 on the Global Market tier of The Nasdaq Stock Market LLC under the symbol LFACU....

TAICHUNG CITY, Taiwan, Dec. 09, 2025 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions across a wide range of applications including personal sports equipment, healthcare products, automobile parts, resin systems, and research and development services, today announced the results of the shareholder votes from its 2025 general meeting of shareholders (the “Meeting”). The Meeting was conducted on December 9, 2025....

CHICAGO, IL, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Meshflow Acquisition Corp. (the “Company”) today announced the pricing of its initial public offering of 30,000,000 units at a price of $10.00 per unit. The units are expected to be listed on The Nasdaq Global Market (“Nasdaq”) and begin trading on December 10, 2025, under the ticker symbol “MESHU”. Each unit consists of one Class A ordinary share and one-third of one redeemable warrant, with each whole warrant exercisable to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. Only whole warrants will be exercisable. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “MESH” and “MESHW,” respectively. The offering is expected to close on December 11, 2025, subject to customary closing conditions....

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock...

Orelabrutinib has demonstrated remarkable efficacy and safety in multiple lymphoma studies, including MZL, MCL, CLL/SLL, PCNSL and DLBCL....

Company prioritizes its interests in other properties, including Airline and Astro Projects Company prioritizes its interests in other properties, including Airline and Astro Projects...

Hong Kong, Dec. 09, 2025 (GLOBE NEWSWIRE) -- JM Group Limited (the “Company” or “JMG”), a Hong Kong-headquartered sourcing and wholesale solutions provider for a wide array of consumer products, today announced the pricing of its initial public offering (the “Offering”) of 3,750,000 ordinary shares (the “Ordinary Shares”) at a public offering price of $4 per share for total gross proceeds of $15,000,000, before deducting underwriting discounts and other offering expenses....

LONG BEACH, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a global leader in launch services and space systems, today announced it is expediting a dedicated Electron mission for the Korea Advanced Institute of Science and Technology (KAIST) and is scheduling the launch from Launch Complex 1 in less than 24 hours' time....

TORONTO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Red White & Bloom Brands Inc. (CSE: RWB) (“RWB” or the “Company”) announces that, further to its news release dated December 1, 2025, it has issued 375,000 common shares at a deemed price of $0.035 per share to a former consultant to settle certain outstanding obligations for past services....

WINNIPEG, Manitoba, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The North West Company Inc. (the "Company" or "North West") today reported its unaudited financial results for the third quarter ended October 31, 2025. It also announced that the Board of Directors has declared a quarterly dividend of $0.41 to shareholders of record on December 31, 2025, to be paid on January 15, 2026....

- Sparta and Warrenton Nursing Facilities and Related Property Sold for $13.18 Million -- Selectis Recaps 2025 Developments and Organizational Outlook -...

SAN CARLOS, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical stage diabetes and obesity company, today announced the release of a KOL interview during the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC 2025) featuring Dr. Ralph DeFronzo, Professor of Medicine and Chief of the Diabetes Division at UT Health San Antonio. The interview highlights the growing body of preclinical and clinical findings supporting the use of icovamenib in patients with diabetes....

Paul Mueller Company today announced the upcoming retirement of Chief Financial Officer Kenneth E. Jeffries and the appointment of Daniel L. Winters as CFO...